Development of synthetic biotics as treatment for human diseases

Advances in synthetic biology have allowed the generation of strains of bacteria that are genetically altered to have specific therapeutic benefits. These synthetic biotics, also widely referred to as engineered living therapeutics, have tremendous potential as a new therapeutic modality, and severa...

Descripción completa

Detalles Bibliográficos
Autor principal: Brennan, Aoife M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944296/
https://www.ncbi.nlm.nih.gov/pubmed/35350191
http://dx.doi.org/10.1093/synbio/ysac001
_version_ 1784673681807507456
author Brennan, Aoife M
author_facet Brennan, Aoife M
author_sort Brennan, Aoife M
collection PubMed
description Advances in synthetic biology have allowed the generation of strains of bacteria that are genetically altered to have specific therapeutic benefits. These synthetic biotics, also widely referred to as engineered living therapeutics, have tremendous potential as a new therapeutic modality, and several have advanced into the clinic and human testing. This review outlines some of the unique attributes of synthetic biotics as well as some of the challenges in their development as prescription products. Regulatory considerations are discussed, and a case study of a program that has advanced into Phase 2 testing is provided: SYNB1618 for the treatment of PKU.
format Online
Article
Text
id pubmed-8944296
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89442962022-03-28 Development of synthetic biotics as treatment for human diseases Brennan, Aoife M Synth Biol (Oxf) Review Article Advances in synthetic biology have allowed the generation of strains of bacteria that are genetically altered to have specific therapeutic benefits. These synthetic biotics, also widely referred to as engineered living therapeutics, have tremendous potential as a new therapeutic modality, and several have advanced into the clinic and human testing. This review outlines some of the unique attributes of synthetic biotics as well as some of the challenges in their development as prescription products. Regulatory considerations are discussed, and a case study of a program that has advanced into Phase 2 testing is provided: SYNB1618 for the treatment of PKU. Oxford University Press 2022-01-31 /pmc/articles/PMC8944296/ /pubmed/35350191 http://dx.doi.org/10.1093/synbio/ysac001 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Brennan, Aoife M
Development of synthetic biotics as treatment for human diseases
title Development of synthetic biotics as treatment for human diseases
title_full Development of synthetic biotics as treatment for human diseases
title_fullStr Development of synthetic biotics as treatment for human diseases
title_full_unstemmed Development of synthetic biotics as treatment for human diseases
title_short Development of synthetic biotics as treatment for human diseases
title_sort development of synthetic biotics as treatment for human diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944296/
https://www.ncbi.nlm.nih.gov/pubmed/35350191
http://dx.doi.org/10.1093/synbio/ysac001
work_keys_str_mv AT brennanaoifem developmentofsyntheticbioticsastreatmentforhumandiseases

Ejemplares similares